MetaCap

IDEAYA Biosciences (IDYA) vs Zai Lab (ZLAB)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Zai Lab (ZLAB) has outperformed IDEAYA Biosciences (IDYA) over the past year, gaining 5.0% versus a loss of 24.8%. Over five years, IDYA leads with a +7.3% price change compared with -72.7% for ZLAB. Zai Lab is the larger company by market cap ($2.63 billion vs $2.47 billion), about 1.1 times the size, while IDEAYA Biosciences is growing revenue faster (+3024.4% vs +15.3%).

Zai Lab converts more of its revenue into profit, with a net margin of -38.1% versus -52.0%.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

IDYA-24.80%ZLAB+5.04%
+38%+5%-28%
Nov 21, 20251 yearNov 20, 2026
IDYA+10.08%ZLAB-75.01%
+112%+10%-93%
Nov 15, 20215 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

IDYA versus ZLAB key metrics
MetricIDYAZLAB
Share price$25.56$21.03
Market cap$2.47B$2.63B
1-day change-2.33%-4.06%
YTD return-26.06%+19.22%
1-year return-24.80%+5.04%
5-year return+7.35%-72.67%
EPS (TTM)$-4.50$-1.80
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)$218.71M$460.16M
Revenue growth (YoY)+3024.43%+15.33%
Net income (latest FY)$-113.70M$-175.54M
Gross margin—58.60%
Operating margin-72.84%-49.86%
Net margin-51.99%-38.15%
52-week high$42.68$29.02
52-week low$25.46$15.96
Distance from 52-week high-40.11%-27.53%
Analyst consensusstrong_buystrong_buy
Avg. price target upside+98.32%+62.67%
Average volume933.58K991.34K
Shares outstanding96.69M124.84M
Employees1451,784
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • ZLAB has outperformed IDYA by 29.8 percentage points over the past year.
  • Zai Lab is more profitable, keeping -38.1 cents of every revenue dollar as net income versus -52.0 cents for IDEAYA Biosciences.
  • IDEAYA Biosciences grew revenue faster in its latest fiscal year (+3024.43% vs +15.33%).

About IDEAYA Biosciences

IDYA stock →

IDEAYA Biosciences, Inc., a precision medicine oncology company, develops targeted therapeutics for patient populations selected using molecular diagnostics in the United States. The company offers Darovasertib, an oral, potent, and selective protein kinase, C (PKC) inhibitor for the treatment of uveal melanoma, ocular cancer, and is being evaluated in multiple clinical trials as monotherapy and in combination with crizotinib for metastatic, neoadjuvant, and adjuvant settings.

Health Care · Biotechnology: Pharmaceutical Preparations · 145 employees

About Zai Lab

ZLAB stock →

Zai Lab Limited, a biopharmaceutical company, focuses on discovering, developing, and commercializing products that address medical conditions in the areas of oncology, immunology, neuroscience, and infectious diseases. Its commercial products include Zejula, an orally administered poly (ADP-ribose) polymerase 1/2 inhibitor for treating ovarian cancer; VYVGART, a human IgG1 antibody fragment for generalized myasthenia gravis and chronic inflammatory demyelinating polyneuropathy; NUZYRA for community-acquired bacterial pneumonia and acute bacterial skin and skin structure infections; Optune for glioblastoma multiforme; Qinlock for gastrointestinal stromal tumors; Xacduro for treating hospital-acquired and ventilator-associated bacterial pneumonia caused by a cinetobacter baumannii-calcoaceticus complex; and Augtyro for the treatment of ROS proto-oncogene 1 and non-small cell lung cancer.

Health Care · Biotechnology: Pharmaceutical Preparations · 1,784 employees

IDYA vs ZLAB FAQ

Which is bigger, IDEAYA Biosciences or Zai Lab?

Zai Lab (ZLAB) is larger, with a market capitalization of $2.63B compared with $2.47B for IDEAYA Biosciences (IDYA).

Which stock has performed better over the past year, IDYA or ZLAB?

ZLAB returned +5.04% over the past 12 months, compared with -24.80% for IDYA (price return, excluding dividends). Past performance does not predict future results.

Are IDEAYA Biosciences and Zai Lab in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons